Caxton Associates LP Has $777,000 Holdings in STAAR Surgical (NASDAQ:STAA)

Caxton Associates LP lessened its position in shares of STAAR Surgical (NASDAQ:STAA) by 67.5% in the first quarter, according to its most recent filing with the SEC. The firm owned 20,307 shares of the medical instruments supplier’s stock after selling 42,106 shares during the quarter. Caxton Associates LP’s holdings in STAAR Surgical were worth $777,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in STAA. Cape Investment Advisory Inc. acquired a new stake in STAAR Surgical during the 4th quarter valued at approximately $42,000. GAMMA Investing LLC grew its position in shares of STAAR Surgical by 313.9% during the 1st quarter. GAMMA Investing LLC now owns 1,308 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 992 shares during the period. Covestor Ltd lifted its holdings in shares of STAAR Surgical by 38.9% in the 1st quarter. Covestor Ltd now owns 2,690 shares of the medical instruments supplier’s stock worth $103,000 after purchasing an additional 754 shares in the last quarter. Quest Partners LLC bought a new position in shares of STAAR Surgical in the 4th quarter worth $146,000. Finally, Perigon Wealth Management LLC lifted its holdings in shares of STAAR Surgical by 10.7% in the 4th quarter. Perigon Wealth Management LLC now owns 7,288 shares of the medical instruments supplier’s stock worth $227,000 after purchasing an additional 703 shares in the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. BTIG Research increased their target price on STAAR Surgical from $46.00 to $53.00 and gave the stock a “buy” rating in a report on Monday, July 15th. Piper Sandler increased their target price on STAAR Surgical from $33.00 to $40.00 and gave the stock a “neutral” rating in a report on Wednesday, May 8th. Mizuho raised their price objective on STAAR Surgical from $53.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, May 8th. William Blair upgraded STAAR Surgical from a “market perform” rating to an “outperform” rating in a research note on Thursday, April 4th. Finally, Morgan Stanley cut STAAR Surgical from an “equal weight” rating to an “underweight” rating and dropped their price objective for the company from $50.00 to $37.00 in a research note on Monday, July 15th. One analyst has rated the stock with a sell rating, six have given a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, STAAR Surgical presently has an average rating of “Hold” and an average price target of $48.00.

STAAR Surgical Stock Performance

Shares of STAA opened at $40.19 on Wednesday. The business has a 50-day moving average of $42.34 and a 200 day moving average of $39.47. STAAR Surgical has a fifty-two week low of $26.66 and a fifty-two week high of $55.38. The firm has a market cap of $1.97 billion, a P/E ratio of 129.65 and a beta of 0.59.

STAAR Surgical (NASDAQ:STAA) last posted its earnings results on Tuesday, May 7th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.12). The company had revenue of $77.40 million for the quarter, compared to analysts’ expectations of $75.34 million. STAAR Surgical had a net margin of 4.69% and a return on equity of 6.83%. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.05 EPS. As a group, research analysts predict that STAAR Surgical will post 0.08 earnings per share for the current fiscal year.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.